PURPOSE: To determine the incidence of trismus in patients who had previously received curative doses of radiation therapy (RT) for head and neck cancer. In addition, we assessed if trismus was associated with quality of life deficits and radiation toxicity. METHODS AND MATERIALS: Between February, 2005 and December, 2006, 40 patients with histologically confirmed head and neck cancer who had received curative doses of RT to the area(s) of the masticatory muscles and/or the ligaments of the temporomandibular joint (TMJ) were enrolled in this study. Differences in trismus incidence were compared between cancer treatment modalities [i.e., RT vs RT/chemotherapy (CT) and conventional RT vs intensity modulated RT]. Quality of life (QOL) was measured by using four questions from the EORTC QLQ-C30 that address pain and difficulty opening the jaw. Scores regarding impaired eating as a result of decreased range of motion of the mouth were derived from the Modified Common Toxicity Criteria (CTCAE Version 3.0). RESULTS: Trismus was identified in 45% of subjects who had received curative doses of RT. No differences were noted in the incidence of trismus between RT and RT/CT or between conventional RT and intensity modulated RT (IMRT). Those with trismus demonstrated more QOL deficits than the non-trismus group. CONCLUSIONS: Curative doses of RT for head and neck cancer result in trismus in a high percentage of patients, independent of other treatment modalities. Trismus has a negative impact on quality of life in this population.
PURPOSE: To determine the incidence of trismus in patients who had previously received curative doses of radiation therapy (RT) for head and neck cancer. In addition, we assessed if trismus was associated with quality of life deficits and radiation toxicity. METHODS AND MATERIALS: Between February, 2005 and December, 2006, 40 patients with histologically confirmed head and neck cancer who had received curative doses of RT to the area(s) of the masticatory muscles and/or the ligaments of the temporomandibular joint (TMJ) were enrolled in this study. Differences in trismus incidence were compared between cancer treatment modalities [i.e., RT vs RT/chemotherapy (CT) and conventional RT vs intensity modulated RT]. Quality of life (QOL) was measured by using four questions from the EORTC QLQ-C30 that address pain and difficulty opening the jaw. Scores regarding impaired eating as a result of decreased range of motion of the mouth were derived from the Modified Common Toxicity Criteria (CTCAE Version 3.0). RESULTS: Trismus was identified in 45% of subjects who had received curative doses of RT. No differences were noted in the incidence of trismus between RT and RT/CT or between conventional RT and intensity modulated RT (IMRT). Those with trismus demonstrated more QOL deficits than the non-trismus group. CONCLUSIONS: Curative doses of RT for head and neck cancer result in trismus in a high percentage of patients, independent of other treatment modalities. Trismus has a negative impact on quality of life in this population.
Authors: W F Regine; J Valentino; W John; G Storey; D Sloan; D Kenady; P Patel; C Pulmano; S M Arnold; M Mohiuddin Journal: Head Neck Date: 2000-09 Impact factor: 3.147
Authors: J Janinis; M Papadakou; G Panagos; A Panousaki; V Georgoulias; D Hatzidaki; D Lefantzis; G Dokianakis Journal: Am J Clin Oncol Date: 2001-06 Impact factor: 2.339
Authors: K T Robbins; P Kumar; F S Wong; W F Hartsell; P Flick; R Palmer; A B Weir; H B Neill; T Murry; R Ferguson; C Hanchett; F Vieira; A Bush; S B Howell Journal: Head Neck Date: 2000-10 Impact factor: 3.147
Authors: George E Maloney; Noshir Mehta; Albert G Forgione; Khalid H Zawawi; Emad A Al-Badawi; Stephen E Driscoll Journal: Cranio Date: 2002-01 Impact factor: 2.020
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Paul Okunieff; Elizabeth Augustine; Jeanne E Hicks; Terri L Cornelison; Rosemary M Altemus; Boris G Naydich; Ivan Ding; Amy K Huser; Edward H Abraham; Judith J Smith; Norman Coleman; Lynn H Gerber Journal: J Clin Oncol Date: 2004-06-01 Impact factor: 44.544
Authors: Michael K Ghiam; Kyle Mannion; Mary S Dietrich; Kristen L Stevens; Jill Gilbert; Barbara A Murphy Journal: Support Care Cancer Date: 2017-02-13 Impact factor: 3.603
Authors: Rene-Jean Bensadoun; Dorothea Riesenbeck; Peter B Lockhart; Linda S Elting; Fred K L Spijkervet; Mike T Brennan Journal: Support Care Cancer Date: 2010-03-06 Impact factor: 3.603
Authors: Shyam D Rao; Ziad H Saleh; Jeremy Setton; Moses Tam; Sean M McBride; Nadeem Riaz; Joseph O Deasy; Nancy Y Lee Journal: Acta Oncol Date: 2015-04-29 Impact factor: 4.089
Authors: Karen E Effinger; Cesar A Migliorati; Melissa M Hudson; Kevin P McMullen; Sue C Kaste; Kathy Ruble; Gregory M T Guilcher; Ami J Shah; Sharon M Castellino Journal: Support Care Cancer Date: 2014-04-30 Impact factor: 3.603